DocWire News Editors

DocwireNews

PHD finger protein 1 9(PHF19), represents a potential therapeutic target to overcome drug resistance and improve outcomes of multiple myeloma (MM) patients, according to a study presented at the 17th International Myeloma Workshop.Researchers assessed the expression of PHF19, a component of the polycomb repressive complex 2, as well as outcomes of MM patients in clinical databases and sequential patient samples. They confirmed the effects of PHF19 on cell growth and drug resistance by overexpression both in vitro and in vivo, respectively. They also used co-IP and western blot assay to confirm molecular mechanism involved in PHF19 functionality.The study results showed that enhanced PHF19 expression is highly linked to high-risk cytogenetic profiles and inferior outcomes of MM patients. They observed that PHF19OE notably enhanced cell proliferation juxtaposed to cells transfected with an empty vector (EV) in both ARP1 and OCI-My5 MM cell lines. They also found that the overexpression of PHF19 led to suppression of apoptosis in ARP1 and OCI-My5 cells exposed to commonly using anti-MM reagents, such as bortezomib (BTZ), epirubicin (EPI), and melphalan (MEL).The researchers also used a xenograft mouse model to evaluate the effects of PHF19 overexpression, and observed that mice engrafted ARP1OE cells had a perceptibly larger tumor volume than the control mice engrafted with ARP1-EV cells. They noted that &ldquo;consistent with our in vitro data, bortezomib injection could not inhibit ARP1-OE cell growth.&rdquo; Overall, the results showed that PHF19 promotes MM cell growth and drug resistance both in vitro and in vivo.&ldquo;Deregulation of miR15a/PHF19/phosphorylation EZH2 patterns participates in disease pathogenesis and progression of MM,&rdquo; the research authors wrote in their conclusion. &ldquo;Our data provides preclinical rational to support the treatment targeting PHF19 to suppress growth and overcome drug resistance in MM and other cancers.&rdquo;Yu T, et al. PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma

International Myeloma Workshop 2019

PHD finger protein 1 9(PHF19), represents a potential therapeutic target to overcome drug resistance and improve outcomes of multiple myeloma patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe